Immune oncology

Show results for

Unknown (35276)
Genomics (859)
Proteomics (144)
Transcriptomics (120)
Models (107)
Metabolomics (17)
Other (10)
Genomic (7)
Clinical (6)
Methylation profiling (6)

Organisms

Homo sapiens (174)
Bombyx mori (117)
Onchocerca volvulus (117)
Klebsiella pneumoniae (117)
Musca domestica (117)
Brugia malayi (117)
Schizosaccharomyces pombe (117)
Cnidaria (117)
Streptomyces coelicolor A3(2) (117)
Sus scrofa (117)
Human immunodeficiency virus 1 (117)
Oryza sativa Indica Group (117)
Sinorhizobium meliloti BL225C (117)
Vitis (117)
Sus scrofa domesticus (117)
Ostreococcus tauri (117)
Saccharomyces cerevisiae (117)
Synechocystis sp. PCC 6803 (117)
Olavius algarvensis Gamma 1 endosymbiont (117)
Mus musculus (59)
Canis lupus familiaris (6)
Rattus norvegicus (3)
Vesicular stomatitis virus (2)
Mus sp. (2)
Gallus gallus (2)
Cancer (1)
Mycobacterium tuberculosis variant bovis BCG (1)
Pasteurella multocida subsp. multocida str. Pm70 (1)
Pseudomonas putida (1)
synthetic construct (1)

Organisms

Homo sapiens (417)
Mus musculus (296)
Canis lupus familiaris (14)
Danio rerio (7)
Rattus norvegicus (3)
Macaca mulatta (2)
Mus musculus albula (1)
Sus scrofa (1)
Gallus gallus (1)
Arabidopsis thaliana (1)
gut metagenome (1)

Repository

ENA (842)
pride (117)
geo (113)
BioModels (107)
biostudies-arrayexpress (28)
MetaboLights (17)
MassIVE (14)
EGA (10)
iProX (9)
dbGaP (7)
GPMDB (3)
PanoramaPublic (3)

Tissue

Cell culture (27)
Epithelial cell (13)
T cell (10)
Lung (8)
Dendritic cell (7)
Blood (5)
Brain (5)
Lymph node (4)
Colon (4)
Spleen (4)
Blood plasma (4)
Macrophage (4)
Liver (4)
Melanocyte (3)
B cell (3)
Kidney (3)
Endothelial cell (2)
Primary cell (2)
Blood platelet (2)
Bone marrow (2)
Fibroblast (2)
Blood serum (2)
Breast (2)
Lymph (2)
Urinary bladder (2)
Wound healing involved in inflammatory response (1)
Mucosal melanoma cell (1)
Monocyte-derived dendritic cell (1)
Left atrium (1)
Cardiac muscle tissue of atrium (1)

Disease

Breast cancer (16)
Cancer (8)
Melanoma (8)
Colon cancer (7)
Acute leukemia (4)
Not Available (3)
Non-small cell lung carcinoma (3)
Malignant neoplasm of ovary (3)
Lung cancer (3)
Lymphoid leukemia (2)
Urinary bladder cancer (2)
Melanoma (2)
Colorectal Neoplasms (2)
Skin melanoma (2)
Renal cell carcinoma (2)
Lymphoma (2)
Kidney cancer (2)
Multiple myeloma (2)
Lung adenocarcinoma (2)
Obesity (2)
Liver carcinoma (2)
Cervix carcinoma (2)
Brain cancer (2)
Disease free (2)
Skin cancer (1)
Glioblastoma multiforme (1)
Non-Hodgkin lymphoma (1)
Normal (1)
Carcinoma (1)
Neoplasms (1)

Technology Type

Mass Spectrometry (117)
Shotgun proteomics (61)
Bottom-up proteomics (21)
Mass spectrometry (14)
Data-dependent acquisition (10)
Affinity purification coupled with mass spectrometry proteomics (9)
SWATH MS (9)
Top-down proteomics (7)
Gel-based experiment (5)
Data-independent acquisition (5)
Mass spectrometry assay (3)
Immunopeptidomics (2)
NMR spectroscopy (1)
Olink affinity proteomics (1)
Affinity proteomics (1)
Glycoproteomics (1)
DiaPASEF (1)
All-ion fragmentation (1)
HDMSE (1)
SRM/MRM (1)

Instrument Platform

Q Exactive (10)
Liquid Chromatography MS - negative - reverse phase (5)
Liquid Chromatography MS - positive - reverse phase (5)
Instrument (3)
Orbitrap Fusion Lumos (3)
Liquid Chromatography MS - positive - reverse-phase (3)
Liquid Chromatography MS - negative - reverse-phase (3)
Liquid Chromatography MS - negative - hilic (3)
Liquid Chromatography MS - positive - hilic (3)
Illumina NovaSeq 6000 (2)
Illumina HiSeq 2000 (2)
Illumina HiSeq 4000 (2)
Orbitrap Fusion (2)
UPLC Q-TOF Premier (Waters) (2)
Genolab M (1)
NextSeq 550 (1)
ThermoFisher Orbitrap (1)
TimsTOF Ultra (Bruker Daltonics timsTOF series) (1)
Orbitrap Fusion ETD (1)
LTQ Orbitrap Elite (1)
TimsTOF SCP (1)
LTQ Orbitrap (1)
Agilent GC/MS, LECO GC/TOFMS (1)
GCT Premier (Waters) (1)
5975C Series GC/MSD (Agilent) (1)
Bruker (1)
Liquid Chromatography MS - (1)
Liquid Chromatography MS - alternating - hilic (1)

Publication Date

2024 (135)
2025 (43)
2026 (39)
2022 (33)
2021 (33)
2023 (32)
2020 (27)
2019 (23)
2018 (10)
2016 (5)
2013 (5)
2011 (5)
2012 (4)
2017 (4)
2015 (3)
2014 (2)
2010 (2)
2009 (2)

UNIPROT ID/AC

P60568 (5)
P01137 (3)
S5S2F2 (1)
Q14609 (1)
C4NUM1 (1)
A2RSY7 (1)
Q0GK43 (1)
Q15116 (1)
P16410 (1)
Q8WXI7 (1)
Q9ES17 (1)
P13232 (1)

CHEBI ID

CHEBI:144829 (6)
CHEBI:25017 (4)
CHEBI:30769 (4)
CHEBI:16525 (3)
CHEBI:36274 (3)
CHEBI:17687 (3)
CHEBI:28683 (3)
CHEBI:18132 (3)
CHEBI:17368 (3)
CHEBI:27471 (3)
CHEBI:16737 (3)
CHEBI:17750 (3)
CHEBI:15354 (3)
CHEBI:16919 (3)
CHEBI:15891 (3)
CHEBI:78320 (3)
CHEBI:30660 (2)
CHEBI:70958 (2)
CHEBI:132966 (2)
CHEBI:17786 (2)
CHEBI:35932 (2)
CHEBI:28946 (2)
CHEBI:18300 (2)
CHEBI:16244 (2)
CHEBI:133185 (2)
CHEBI:40410 (2)
CHEBI:25858 (2)
CHEBI:4027 (1)
CHEBI:28748 (1)
CHEBI:17234 (1)

Metabolite Name

Sphingosine 1-phosphate (2)
Glycodeoxycholic acid (GDCA) (2)
N1-Methyl-2-pyridone-5-carboxamide (2)
Cholesterol (2)
Valine (2)
Tryptophan (2)
Isoleucine (2)
Kynurenine (2)
N-acetyltryptophan (2)
LPE (0:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (1)
LPE (22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0) (1)
LPE (0:0/20:4(8Z,11Z,14Z,17Z)) (1)
LPE (20:4(8Z,11Z,14Z,17Z)/0:0) (1)
LPE (0:0/20:4(5Z,8Z,11Z,14Z) (1)
LPE (20:4(5Z,8Z,11Z,14Z)/0:0) (1)
Lythramine|cytochalasin B (1)
4-trifluoro methylaniline (1)
PS (O-18:0/0:0) (1)
LPE (20:3) (1)
LPC (15:0) (1)
Fragment of GCA (1)
Fragment of GDCA/GCDCA (1)
Taurochenodeoxycholic acid (TCDCA) (1)
Taurocholic acid (TCA) (1)
Unidentified (UM 232; RT 808) (1)
Alpha tocopherol (1)
Sebacate (decanedioate) (1)
Retinol (Vitamin A) (1)
Margaroylcarnitine (1)
Dihomo-linoleate (20:2n6) (1)

First Public Date

2024 (153)
2025 (144)
2026 (125)
2023 (90)
2022 (80)
2020 (71)
2021 (66)
2014 (39)
2019 (24)
2017 (19)
2015 (12)
2018 (11)
2016 (7)
2013 (1)

Modelling Approach

Ordinary differential equation model (97)
Random forest procedure (1)
Computational model (1)
Delayed differential equation model (1)

Study status

Withdrawn (2)
Recruiting (2)
Active, not recruiting (1)
Completed (1)

Lab affiliation

Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, Netherlands (6)
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China (3)
Departments of Immunology and Radiation Oncology Moffitt Cancer Center Tampa, FL, USA (2)
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, China (2)
Division of Surgery, Oncology, and Pathology, Department of Clinical Sciences, Lund University, Solvegatan 19, 223 62, Lund, Sweden. (2)
University of Lübeck Section for Translational Surgical Oncology & Biobanking Department of Surgery Ratzeburger Allee 160, BMF 23558 Lübeck, Germany (2)
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia (2)
Department of Oncology-Pathology, Karolinska Institute and Scilifelab, Solna, Sweden (2)
Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Office B25A/04/94 Rue du Bugnon 25a, CH-1005 Lausanne (2)
European Institute of Oncology, Milan, Italy (2)
State Key Laboratory of Oncology in South China (2)
Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC) (1)
Department of Hematology and Oncology, University of Tübingen, Germany (1)
Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA (1)
Laboratory for RNA Cancer Biology Department of Oncology, LKI, KU Leuven (1)
Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Rue du Bugnon 25a, CH-1005 Lausanne (1)
Full professor, Federal University of São Paulo, Brazil. (1)
OmicScouts GmbH Lise-Meitner-Str. 30 D-85354 Freising Germany (1)
Dr Michal BASSANI-STERNBERG ¬ Group leader Laboratory Hi-TIDe: Immunopeptidomics Head of clinical Mass spectrometry unit Center of experimental therapeutics Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Biopôle 3 Chemin des Boveresses 155, CH-1066 Lausanne (1)
Center of experimental therapeutics Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Centre de recherche Agora Rue du Bugnon 25A CH-1005 Lausanne (1)
1Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA (1)
Scientist, IR-MUHC, Glen site Cancer Research Program Center for Translational Biology Assistant Professor, Gerald Bronfman Department of Oncology, Faculty of Medicine and Health Sciences, McGill University (1)
Professor of Cell Signalling & Proteomics Centre for Genomics and Computational Biology Barts Cancer Institute Queen Mary, University of London John Vane Science Centre, Charterhouse Square, London EC1M 6BQ Tel: +44 (0)20 7882 8266 | Fax: +44 (0)20 7882 3891 (1)
Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Victoria 3000, Australia (1)
Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research and Jewish General Hospital, and McGill University, Montréal, Québec, Canada Gerald Bronfman Department of Oncology, McGill University, Montréal, Québec, Canada (1)
Department of Radiation Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston MA 02215 (1)
Department of Oncology and Pathology, Karolinska Institute; Science for Life Laboratory, Stockholm, Sweden (1)
Radiation Oncology Department Weill Cornell Medicine College 1300 York Avenue, NY, NY 10065 (1)
Radiation Oncology; Weill Cornell medicine College; 1300 York Avenue; 10065, New York, New York, USA (1)
Molecular Oncology Lab, La Paz University Hospital, Paseo de la Castellana 261, 28046, Madrid, Spain (1)

Keyword

Intestinal microbiota, microbial genes, oncology (1)
Bi-Sialidase (1)
Anti-Tumor (1)
E-602 (1)
Cemiplimab (1)
Poly(I).poly(c12,U) (1)
Pembrolizumab (1)

IsPrivate

False (107)

Submitter Keywords

Immuno-oncology (101)
Oncology (2)
Machine Learning Model (2)
FAIR-AIML (1)

Study type

Transcription profiling by array (15)
RNA-seq of coding RNA (5)
Interventional (5)
RNA-seq of coding RNA from single cells (3)
ChIP-seq (2)
Human - High-throughput sequencing (1)
Human - One-color microarray (1)
Methylation profiling by array (1)
Observational (1)

Release Date

2022 (5838)
2025 (5157)
2023 (4961)
2021 (4643)
2024 (4137)
2020 (2912)
2019 (1755)
2018 (1358)
2017 (971)
2016 (854)
2015 (614)
2026 (607)
2014 (473)
2013 (247)
2012 (225)
2011 (164)
2009 (114)
2010 (112)
2008 (49)
2007 (34)
2006 (25)
2005 (20)
2001 (8)
2003 (7)
2004 (5)
2002 (5)
2000 (4)
1998 (3)
1997 (1)

Location

United States (4)
France (2)

Previous page
1 / 3656
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 3656
Next page

Sort by:

Relevance

Page size

A Single-Cell Tumor Immune Atlas for Precision Oncology

PRJNA666613 | ENA

A Single-Cell Tumor Immune Atlas for Precision Oncology

The tumor immune microenvironment is a main contributor to cancer progression and a promising therapeutic target for oncology. However, immune microenvironments vary profoundly between patients and biomarkers for prognosis and treatment response lack precision. A comprehensive compendium of tumor im...

ORGANISM(S): Homo sapiens Mus musculus

2020-10-27 | GSE158803 | GEO

Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study.

Not available

S-EPMC11761430 | biostudies-literature

Integration of functional precision oncology to immune contexture predicts immunotherapies strategies for mucosal melanomas.

PRJNA1213138 | ENA

Creemers2021 - Tumor-immune dynamics and implications on immunotherapy responses

This ordinary differential equation model simulating the mechanisms that govern cancer-immune dynamics and their role in tumor responses to immunotherapy is described by the publication: Creemers JHA, Lesterhuis WJ, Mehra N, et al. "A tipping point in cancer-immune dynamics leads to divergent immuno...

2024-09-02 | BIOMD0000001022 | BioModels

Immuno-oncology